Efficacy and Toxicity of Pemigatinib in Advanced Cholangiocarcinoma Harboring FGFR Fusions or Rearrangements: A Systematic Review and Meta-analysis
Targeted Oncology · 2025
DOI: 10.1007/s11523-025-01142-8 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Targeted Oncology, 2025. Verfasst von Erman Akkus und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Pyrimidines, Bile Duct Neoplasms, Morpholines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The efficacy and safety of pemigatinib in advanced cholangiocarcinoma (aCCA) were presented in phase I-II trials and retrospective reports, with small sample sizes and variable results. METHODS: A systematic literature search included studies investigating the efficacy/safety of pemigatinib in aCCA harboring FGFR fusions/rearrangements. Primary outcomes were objective response rate (ORR) and treatment-related adverse events (AEs). A pooled proportion meta-analysis was performed. RESULTS: Three hundred and twenty-seven patients in eight studies were included (three phase-II, one phase-I/II, two phase-I, and two retrospective). In the pooled analyses, the median age was 58.9 years (95% confidence interval (CI): 51.9-65.8); 33.4% (95% CI: 28.1-39.0) were male. Pemigatinib was the second-line treatment in 58.5% (95% CI: 52.7-64.1) and was beyond second-line in the remaining. ORR was 42.2% (95% CI: 35.9-48.7) (I2:48.4%) and disease control rate (DCR) was 86.5% (95% CI: 81.6-90.5) (I2: 58.8%). Median progression-free survival (PFS) was 7.8 months (95% CI: 6.2-9.4) (I2: 11.6%). Two studies reported overall survival (OS) (median 17.5 and 17.1 months). The most common AEs (any grade) were hyperphosphatemia (46%), dysgeusia (33.2%), alopecia (31.4%), fatigue (30.9%), stomatitis (28.5%), and diarrhea (27.5%). Cumulative eye and nail toxicities were observed in 32.5% and 40.9%, and retinal detachment in 5.5%. CONCLUSION: This analysis emphasizes the FGFR alteration testing and pemigatinib use in the second-line and beyond treatment of aCCA. REGISTRATION ID (PROSPERO): CRD42024627459.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey.
- Ankara University Cancer Research Institute, Ankara, Turkey.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
- Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
- Department of Oncology, OncoHealth Institute, Instituto de Investigaciones Sanitarias FJD, Fundación Jiménez Díaz University Hospital, Avda Reyes Catolicos 2, 28040, Madrid, Spain. angela.lamarca@quironsalud.es.
Zitieren
APA
Akkus, E., Yasar, H. A., Rimassa, L., & Lamarca, A. (2025). Efficacy and Toxicity of Pemigatinib in Advanced Cholangiocarcinoma Harboring FGFR Fusions or Rearrangements: A Systematic Review and Meta-analysis. Targeted Oncology. https://doi.org/10.1007/s11523-025-01142-8
Vancouver
Akkus E, Yasar HA, Rimassa L, Lamarca A. Efficacy and Toxicity of Pemigatinib in Advanced Cholangiocarcinoma Harboring FGFR Fusions or Rearrangements: A Systematic Review and Meta-analysis. Targeted Oncology. 2025. doi:10.1007/s11523-025-01142-8
BibTeX
@article{Akkus2025,
author = {Akkus, Erman and Yasar, Hatime Arzu and Rimassa, Lorenza and Lamarca, Angela},
title = {Efficacy and Toxicity of Pemigatinib in Advanced Cholangiocarcinoma Harboring FGFR Fusions or Rearrangements: A Systematic Review and Meta-analysis},
journal = {Targeted Oncology},
year = {2025},
doi = {10.1007/s11523-025-01142-8}
}
EUVIMED